Remove 2020 Remove Cannabinoids Remove Clinical Trials
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

Clinical Trial: Oral THC Administration Associated with Opioid-Sparing Effects

NORML

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Additional information on the relationship between cannabis and opioids is available in the NORML fact-sheet here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

.” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. ” The agency is accepting public comments through June 16, 2020.

article thumbnail

Cannabinoids for Tinnitus?

Project CBD

I nterestingly, and perhaps unfortunately for patients, previous reviews in 2020 and 2019 2 also concluded there was insufficient evidence that cannabis can diminish chronic tinnitus. There could be a role for cannabinoids in the management of tinnitus through their anticonvulsant effects. And its conclusion?

article thumbnail

Review Paper: Clinical Evidence Lacking in Support of CBD as an Anti-Viral Agent

NORML

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.

CBD 323
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. SOURCE InMed Pharmaceuticals Inc.